{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:52:11Z","timestamp":1753890731857,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Osteoporosis is common in post-polio clinic patients, and is reported in 30%to 50% of middle-aged individuals with previous polio. The levels of bone biomarkers (calcium regulating hormones, bone metabolism markers, and bone turnover markers), and the response of bone turnover markers to bisphosphonates is unknown in post-polio patients with osteoporosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>1) To describe serum levels of bone biomarkers in post-polio clinic patients with osteoporosis and compare these levels to those in controls with osteoporosis without neurological disease. 2) To examine the change in serum levels of bone biomarkers in post-polio patients following at least six months of treatment with bisphosphonates and compare these changes to controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective chart review of Post-Polio and Bone Metabolism Clinic charts of our center. Patients without osteoporosis, and incomplete lab data were excluded. For the second objective, patients untreated with bisphosphonates were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean age and proportion of females were similar in post-polio patients (n=25) and controls (n=31) (66.3 \u00b1 8.1 vs 66.2 \u00b1 10.9 years, 52% vs 61%). Mean baseline serum levels of calcium, calcium regulating hormones [parathyroid hormone (PTH), 25-hydroxy Vitamin D), and serum bone turnover makers (sBTM\u2019s; osteocalcin, C-telopeptide, non-specific alkaline phosphatase (ALP)] were normal. PTH (4.4 \u00b1 1.7 vs 5.5 \u00b1 2.3 pmol\/L, p=0.05), ALP (63.9 \u00b1 15.8 vs 76.2 \u00b1 26.7 U\/L, p=0.04), osteocalcin (18.3 \u00b1 8.8 vs 26.9 \u00b1 8.4 ng\/ml, p&amp;lt;0.01), and C-telopeptide (0.35 \u00b1 0.2 vs 0.55 \u00b1 0.21 microgram\/L, p=0.01) were significantly lower in post-polio patients. After \u2265 six months of treatment with bisphosphonates, sBTM\u2019s declined significantly in both groups, with a significantly greater reduction in controls for osteocalcin (p&amp;lt;0.01) and C-telopeptide (p=0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While mean levels of all evaluated bone biomarkers were normal, PTH and sBTMs were significantly lower in post-polio patients with osteoporosis compared to controls, indicating reduced bone turnover. With bisphosphonate treatment, osteocalcin and C-telopeptide declined significantly in both groups, but significantly more in controls than in post-polio patients. These results indicate that BTM\u2019s could be useful for monitoring treatment response in post-polio patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1568981","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:11:03Z","timestamp":1749183063000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone biomarkers in post-polio clinic patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Seyed Pezhman","family":"Madani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Grunbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaddam","family":"Bagmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria A.","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mus.20259","article-title":"Post-poliomyelitis syndrome","volume":"31","author":"Trojan","year":"2005","journal-title":"Muscle Nerve"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.04.018","article-title":"Post-poliomyelitis syndrome as a possible viral disease","volume":"35","author":"Baj","year":"2015","journal-title":"Int J Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26167","article-title":"Post-polio syndrome and the late effects of poliomyelitis: Part 2. treatment, management, and prognosis","volume":"58","author":"Lo","year":"2018","journal-title":"Muscle Nerve"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000242444","article-title":"High incidence of osteoporosis and fractures in an aging post-polio population","volume":"62","author":"Mohammad","year":"2009","journal-title":"Eur Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2014.09.011","article-title":"The relationship between body composition and femoral neck osteoporosis or osteopenia in adults with previous poliomyelitis","volume":"8","author":"Chang","year":"2015","journal-title":"Disabil Health J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.05.010","article-title":"Osteoporosis in a postpolio clinic population","volume":"88","author":"Haziza","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S138000","article-title":"A comprehensive overview on osteoporosis and its risk factors","volume":"14","author":"Pouresmaeili","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1969","article-title":"Bone and skeletal muscle: neighbors with close ties","volume":"28","author":"DiGirolamo","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000603","article-title":"Bones and muscular dystrophies: what do we know","volume":"31","author":"Wood","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2020-0102","article-title":"The risk of bone fractures in post-poliomyelitis patients transitioning to middle adulthood","volume":"26","author":"Sherf","year":"2020","journal-title":"Endocr Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00002060-200208000-00002","article-title":"Polio survivors: falls and subsequent injuries","volume":"81","author":"Silver","year":"2002","journal-title":"Am J Phys Med Rehabil"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-019-04285-2","article-title":"Outcome of femoral fractures in poliomyelitis patients","volume":"43","author":"Gellman","year":"2019","journal-title":"Int Orthop"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40842-018-0062-7","article-title":"The challenges of diagnosing osteoporosis and the limitations of currently available tools","volume":"4","author":"Choksi","year":"2018","journal-title":"Clin Diabetes Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2020.27.4.237","article-title":"Does hip bone density differ between paretic and non-paretic sides in hemiplegic stroke patients? and its relationship with physical impairment","volume":"27","author":"Lee","year":"2020","journal-title":"J Bone Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"Sozen","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"B16","first-page":"92","article-title":"Osteoporosis: A review of treatment options","volume":"43","author":"Tu","year":"2018","journal-title":"P T"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2020-0073","article-title":"Effects of bisphosphonates on osteoporosis induced by duchenne muscular dystrophy: A prospective study","volume":"26","author":"Zheng","year":"2020","journal-title":"Endocr Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2010.08.009","article-title":"Response of postpoliomyelitis patients to bisphosphonate treatment","volume":"2","author":"Alvarez","year":"2010","journal-title":"PM R"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acc.2017.06.005","article-title":"Calcium and bone metabolism indices","volume":"82","author":"Song","year":"2017","journal-title":"Adv Clin Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16041","DOI":"10.1038\/boneres.2016.41","article-title":"Vitamin D, calcium homeostasis and aging","volume":"4","author":"Veldurthy","year":"2016","journal-title":"Bone Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2020.612366","article-title":"Effects of neurological disorders on bone health","volume":"11","author":"Kelly","year":"2020","journal-title":"Front Psychol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3803\/EnM.2020.35.1.55","article-title":"Potential biomarkers to improve the prediction of osteoporotic fractures","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.192914","article-title":"Bone turnover markers: Emerging tool in the management of osteoporosis","volume":"20","author":"Shetty","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2019.26.4.213","article-title":"Position statement on the use of bone turnover markers for osteoporosis treatment","volume":"26","author":"Park","year":"2019","journal-title":"J Bone Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0097-4","article-title":"Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives","volume":"5","author":"Kuo","year":"2017","journal-title":"biomark Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3949\/ccjm.90a.22002","article-title":"Bone turnover markers to monitor oral bisphosphonate therapy","volume":"90","author":"Ashcherkin","year":"2023","journal-title":"Cleve Clin J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.11.005","article-title":"Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population","volume":"83","author":"Dai","year":"2016","journal-title":"Bone"},{"key":"B29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/1872214809666150806105433","article-title":"Biochemical markers of bone turnover and their role in osteoporosis diagnosis: A narrative review","volume":"9","author":"Khashayar","year":"2015","journal-title":"Recent Pat Endocr Metab Immune Drug Discovery"},{"volume-title":"Assessment of fracture risk and its application to screening for post menopausal osteoporosis","year":"1994","author":"Organization","key":"B30"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9993(94)90134-1","article-title":"Predictive factors for post-poliomyelitis syndrome","volume":"75","author":"Trojan","year":"1994","journal-title":"Arch Phys Med Rehabil"},{"volume-title":"RStudio: integrated development for R","year":"2019","key":"B32"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14487","article-title":"Quantitative prediction of bone mineral density by using bone turnover markers in response to antiresorptive agents in postmenopausal osteoporosis: A model-based meta-analysis","volume":"87","author":"Wu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.52.667","article-title":"Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis","volume":"52","author":"Kim","year":"2005","journal-title":"Endocr J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1017\/S0954422414000183","article-title":"Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products","volume":"27","author":"Bonjour","year":"2014","journal-title":"Nutr Res Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.18502\/ijph.v51i2.8681","article-title":"The effects of vitamin D fortified products on bone biomarkers: A systematic review and meta-analysis","volume":"51","author":"Emadzadeh","year":"2022","journal-title":"Iran J Public Health"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2999","article-title":"Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate","volume":"97","author":"Olmos","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1568981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:11:04Z","timestamp":1749183064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1568981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":37,"alternative-id":["10.3389\/fendo.2025.1568981"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1568981","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1568981"}}